On June 21, 2023 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), reported that the International Nonproprietary Name (INN) for AMP945 is narmafotinib (Press release, Amplia Therapeutics, JUN 21, 2023, View Source;[email protected] [SID1234632802]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The process for naming a drug compound requires an extensive process of review prior to approval. These reviews take into account similarity with other drug names, ease of pronunciation across multiple languages, language review for accidental meaning, and finally a period for parties to report an objection to the name. With these processes now complete the Company is now free to use the name narmafotinib for AMP945.

Amplia’s CEO and Managing Director, Dr Chris Burns, commented: "Approval of the name narmafotinib is an important step in the commercial development of the drug, signalling to potential partners and collaborators our commitment to the long-term development of this exciting agent.